Q-omics provides the consensus-scored TCF12 profile across patient tissues and cancer cell-line models. TCF12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TCF12 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TCF12 protein abundance shows 25,131 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where TCF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF12 survival associations across molecular data types. TCF12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF12 RNA expression–survival associations across cancer types. High TCF12 expression shows unfavorable associations in UVM, ACC, BLCA and MESO, but favorable associations in LGG and GBM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TCF12 RNA expression.
This table summarizes TCF12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCF12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF12 shows lower tumor expression in THCA and higher tumor expression in CHOL, READ, LIHC, HNSC and STAD. The THCA box plot shows higher TCF12 RNA expression in normal versus tumor tissue (log2 FC = −0.455, t-test p < 0.001).
This table shows molecular features associated with TCF12 in patient tissues and cancer cell lines. In patient samples, TCF12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
